GSK 2696277

Drug Profile

GSK 2696277

Alternative Names: Autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene

Latest Information Update: 15 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Fondazione Telethon; GlaxoSmithKline; Ospedale San Raffaele
  • Class Gene therapies; Stem cell therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Beta-thalassaemia

Most Recent Events

  • 09 Dec 2017 Efficacy data from the phase I/II TIGET-BTHAL trial in Beta-thalassaemia presented at the 59th American Society of Hematology Annual Meeting (ASH-2017)
  • 04 Oct 2017 Phase-II clinical trials in Beta-thalassaemia (In children, In adolescents, In adults, In the elderly) in Italy (Intraosseous) (NCT03275051)
  • 12 Sep 2017 GlaxoSmithKline plans a phase II trial for Beta-thalassaemia (In children, In adults, In adolescents, In elderly) (Intraosseous) (NCT03275051)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top